Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to CONTROLLED MEDICINES

The New England Journal of Medicine

Perspective: How Should the FDA Evaluate Psychedelic Medicine?

Psychiatry November 14th 2023

Psych Congress Network

FDA Issues Warning Highlighting Risks of Ketamine for Psychiatric Disorder Treatment

Psychiatry November 7th 2023


The Controversy Surrounding Ketamine Continues. Should You Be Prescribing It?

Neurology November 7th 2023

Psych Congress Network

DEA Extends Temporary Telehealth Prescribing Rules but Long-Term Investment Needed, Expert Says

Psychiatry November 1st 2023

Medical Professionals Reference (MPR)

Safety Concerns Prompt FDA Warning for Compounded Ketamine Products

Psychiatry October 18th 2023

Specialty Pharmacy Continuum

Adaptation Is Needed To Prevent Diversion In Community Pharms

Clinical Pharmacology September 29th 2023

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form